期刊文献+

基于金属的神经退行性疾病治疗策略 被引量:2

Metal-Based Therapeutic Strategies of Neurodegenerative Diseases
原文传递
导出
摘要 本文综述了金属离子在神经退行性疾病中的重要作用以及针对该类疾病金属治疗药物的研究进展。以老年痴呆症和帕金森氏症为代表,结合本课题组的初步研究结果,讨论了金属离子在蛋白质聚集与氧化应激反应中的重要作用,暗示金属螯合策略应成为治疗该类疾病的首选策略,并介绍了数种已用于或即将用于临床实验的金属螯合制剂;还介绍了烷基化神经退行性疾病相关蛋白的金属结合位点,可以显著抑制该蛋白质聚集体的形成和活性氧的产生,这可能是继螯合策略后一种更有发展潜力的神经退行性疾病治疗方法。 The role of metal ions in both the pathology of neurodegenerative diseases and their treatments are summarized. The metal ion-mediated protein aggregation and oxidative stress in such as Alzheimer's and Parkinson's are discussed by integrating our preliminary data. The progress obtained to date shows that the metal chelation might be a preferred strategy in treatments of neurodegenerative diseases. Thus, a number of metal-chelating agents have been introduced into clinical trials. The alkylation of metal binding sites in the disease-linked proteins can significantly inhibit the formation of protein aggregates and reactive oxygen species, suggesting that this strategy may be a potential method totreat the diseases.
出处 《化学进展》 SCIE CAS CSCD 北大核心 2009年第5期903-910,共8页 Progress in Chemistry
基金 国家自然科学基金项目(No.20571028) 农药与化学生物学教育部重点实验室项目(No.200601A04) "国家大学生创新性实验计划"资助
关键词 神经退行性疾病 氧化应激 蛋白质聚集 金属离子 螯合治疗 neurodegenerative diseases oxidative stress protein aggregation metal ions metal chelator
  • 相关文献

参考文献54

  • 1陈玉静,田金洲.阿尔茨海默病是另外一种形式的糖尿病[J].中国老年学杂志,2008,28(4):402-404. 被引量:11
  • 2Dobson C M. Trends Biochem. Sci., 1999, 24:329--332.
  • 3Soto C. FEBS Lett., 2001, 498 : 204--207.
  • 4Curtain C C, All F, Volitakis I, et al. J. Biol. Chem., 2001, 276 : 20466--20473.
  • 5Crichton R R, Dexter D T, Ward R J, Coord, Chem. Rev., 2008, 252:1189--1199.
  • 6Carlos 0 D, Huang X D, Robert A C. J. Biol. Chem., 2002, 277: 40302--40308.
  • 7Atwood C S, Obrenovich M E, Liu T, et al. Brain Res. Rev., 2003, 43:1--16.
  • 8Ha C, Ryu J, Park C B. Biochemistry, 2007, 46:6118--6125.
  • 9Dong J, Canfield J M, Mehta A K, et al. Proc. Natl. Acad. Sci. USA, 2007, 104:13313--13318.
  • 10Burdette S C, Lippard S J. Proe. Natl. Acad. Sei. USA, 2003, 100:3605--3610.

二级参考文献58

  • 1冀瑞俊,贾建平.糖尿病患者总体认知功能和认知功能域的研究[J].中国临床康复,2004,8(21):4133-4135. 被引量:20
  • 2Liu C W,Giasson B I,Lewis K A,et al.A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation:implications for pathogenesis of Parkinson disease.J Biol Chem,2005,280 (24):22670~22678
  • 3Hashimoto M,Takeda A,Hsu L J,et al.Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease.J Biol Chem,1999,274 (41):28849~28852
  • 4Engelender S,Kaminsky Z,Guo X,et al.Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions.Nat Genet,1999,22 (1):110~ 114
  • 5Cole N B,Murphy D D,Lebowitz J,et al.Metal-catalyzed oxidation of alpha-synuclein:helping to define the relationship between oligomers,protofibrils and filaments.J Biol Chem,2005,280 (10):9678~9690
  • 6Maroteaux L,Campanelli J T,Scheller R H.Synuclein:a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.J Neurosci,1988,8 (8):2804~2815
  • 7Conway K A,Lee S J,Rochet J C,et al.Acceleration of oligomerization,not fibrillization,is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease:implications for pathogenesis and therapy.Proc Natl Acad Sci USA,2000,97 (2):571~576
  • 8Kessler J C,Rochet J C,Lansbury P T Jr,et al.The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.Biochemistry,2003,42 (3):672~678
  • 9Bodles A M,Guthrie D J,Harriott P,et al.Toxicity of non-abeta component of Alzheimer's disease amyloid,and N-terminal fragments thereof,correlates to formation of beta-sheet structure and fibrils.Eur J Biochem,2000,267 (8):2186~2194
  • 10Giasson B I,Murray I V,Trojanowski J Q,et al.A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.J Biol Chem,2001,276 (4):2380~2386

共引文献20

同被引文献21

  • 1薛寿儒,杨小旺.血小板β-淀粉样肽前体蛋白免疫强度及异构体比率对Alzheimer病的诊断价值[J].临床神经病学杂志,2007,20(3):176-178. 被引量:5
  • 2彭荣飞,林国帧,甘平胜,黄聪.碰撞池ICP-MS直接测定全血中痕量金属元素的研究[J].中国卫生检验杂志,2007,17(8):1433-1435. 被引量:21
  • 3Gaeta A,Hider RC. The crucial role of metal ions in neurodegeneration:the basis for a promising therapeutic strategy[J].British Journal of Pharmacology,2005.1041.
  • 4Huang Y,Mucke L. Alzheimer mechanisms and therapeutic strategies[J].Cell,2012.1204.
  • 5McKeith IG,Dickson DW,Lowe J. Diagnosis and management of dementia with Lewy bodies:third report of the DLB Consortium[J].Neurology,2005.1863.
  • 6Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease[J].Journal of Alzheimer's Disease,2008.223.
  • 7Roos PM,Vesterberg O,Nordberg M. Metals in motor neuron diseases[J].Experimental Biology and Medicine(Maywood),2006.1481.
  • 8Dubois B,Feldman HH,Jacova C. Research criteria for the diagnosis of Alzheimer's disease:revising the NINCDS-ADRDA criteria[J].Lancet Neurology,2007.734.
  • 9Gerhardsson L,Lundh T,Minthon L. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease[J].Dementia and Geriatric Cognitive Disorders,2008.508.
  • 10Oteiza PI,Mackenzie GG,Verstraeten SV. Metals in neurodegeneration:involvement of oxidants and oxidant-sensitive transcription factors[J].Molecular Aspects of Medicine,2004.103.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部